It increases glucose levels in pathophysiological conditions depending on the time it is injected into the body. Fludeoxyglucose F-18 transport and phosphorylation used to evaluate glucose metabolism. After intravenous administration, it quickly distributes to all organs of the body. Glucose metabolism in cancer cells is reflected by the accumulated Fludeoxyglucose F-18 under positron emission tomography (PET).
Optimal PET imaging is usually achieved 30-40 minutes after administration by Fludeoxyglucose (18F) radionuclide injection. Fludeoxyglucose F-18 accumulation may be increased, normal, or decreased depending on the tumor type, stage, and location. Fludeoxyglucose F-18 Injection is typically stored at 25°C (77°F). Allowable excursions to 15-30°C in lead-shielded containers.
Get Sample Copy of This Report @ https://www.persistencemarketresearch.com/samples/17275
Advances in radiopharmaceutical technology, along with improvements in hardware and software in PET imaging, are major factors driving the growth of the Fludeoxyglucose (18F) radionuclide implantation market. Moreover, improved diagnostic accuracy and low risk associated with this injection will be responsible for the strong growth of the Fludeoxyglucose (18F) radionuclide injection market.
Increasing prevalence of cancer and cardiovascular disease will also significantly drive the growth of this market. The focus of key market players working with regional and regional players will be an absolute opportunity for the growth of this Fludeoxyglucose (18F) Radionuclide Injection market. The high cost of Fludeoxyglucose (18F) Radionuclide Injection will restrain the growth of this market. Lack of skilled professionals in low-economy countries will also hamper the growth of this market.
The global Fludeoxyglucose (18F) radionuclide injection market is segmented on the basis of indication and end user.
| display criteria |
|
| By end-user |
|
For a complete list of market participants, please request a table of contents at https://www.persistencemarketresearch.com/toc/17275
Fludeoxyglucose (18F) radionuclide injection market is expected to witness significant growth during the forecast period owing to the increasing cancer prevalence across the globe. According to the World Health Organization (WHO), 14.1 million cases of cancer were registered worldwide in 2012. The WHO also found that more than 33% of cancer cases are related to smoking and chewing tobacco.
The global market for Fludeoxyglucose (18F) Radionuclide Injection can be segmented on the basis of indications and end users. On the basis of indication, the Fludeoxyglucose (18F) Radionuclide Injection Market can be segmented into Cancer, Coronary Artery Disease and Other. The Fludeoxyglucose(18F) Radionuclide Injection Market by End User is segmented into Hospitals, Clinics, and Diagnostic Centers. Among end users, hospitals are expected to gain the largest share of value during the forecast period and diagnostic centers are expected to grow at the highest CAGR.
The global Fludeoxyglucose (18F) radionuclide injection market is segmented into five major regions. North America, Latin America, Europe, Asia Pacific and Middle East and Africa. North America is expected to dominate the global Fludeoxyglucose (18F) radionuclide injection market owing to its high healthcare infrastructure. After North America, the Fludeoxyglucose (18F) radionuclide injection market is followed by Europe and Asia Pacific. The European market is expected to grow owing to the increasing number of manufacturers of Fludeoxyglucose(18F) Radionuclide Injection. In the Asia-Pacific region, India and China are projected to be major markets due to the increasing elderly population and cancer incidence.
Pre-order now for exclusive analyst support @ https://www.persistencemarketresearch.com/checkout/17275
Some market players in the fludeoxyglucose (18F) radionuclide infection market identified across the value chain include Zevacor Pharma, Inc., Queen’s PET Imaging Center, LLC, Triad Isotopes, Inc., NCM USA Bronx LLC, Spectron MRC, LLC, and Petnet Solutions. , Inc, Shertech Laboratories, LLC, Precision Nuclear LLC.
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com